CAR-T Cells Targeting Autoimmune Diseases

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT05459870
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • 4SCAR T cells — BIOLOGICAL
    Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV

Study Details

The purpose of this study is to assess the feasibility, safety and efficacy of CAR-T cell therapy in patients with autoimmune disease. Another goal of the study is to learn more about the safety and function of the CAR-T cells and their persistency in autoimmune disease patients.

Key Dates

First listed
Jul 15, 2022
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 4SCAR T Cell Therapy for autoimmune diseases

Primary Outcome Measure

Safety of 4SCAR T cells in patients with autoimmune diseases [ Time Frame: 12 weeks ]

Central Contacts

Related Studies